Clinical Edge Journal Scan

Presence of Central Sensitization Should Be Considered During PsA Treatment


 

Key clinical point: Nearly two out of three patients with psoriatic arthritis (PsA) had clinically significant central sensitization (CS), with the severity of psoriasis, anxiety level, and sleep quality being independent predictors of worse CS Inventory (CSI) scores.

Major finding: Overall, 65.1% patients had clinically significant CS, with a CSI score ≥ 40, with the severity of psoriasis and disease activity scores for PsA being positively associated with CSI scores (correlation coefficient 0.393-0.652; P < .001). The Psoriasis Area Severity Index (odds ratio [OR] 9.70; P = .017), General Anxiety Disorder-7 (OR 2.89; P = .014), and Insomnia Severity Index (OR 5.56; P = .041) scores were independent predictors of CS.

Study details: This cross-sectional observational study included 103 patients with PsA (age 18-75 years) with a mean CSI score of 45.4.

Disclosures: This study did not receive any financial support. The authors declared no conflicts of interest.

Source: Kaya MN, Tecer D, Kılıç Ö, et al. Impact of central sensitization on clinical and functional aspects of psoriatic arthritis. Medicina. 2024;60(9):1449 (Sept 4). Source

Recommended Reading

Topical Tapinarof and Roflumilast for Psoriasis: Where Do they Fit In?
MDedge Rheumatology
Apremilast Effective in Early PsA With Limited Joint Involvement
MDedge Rheumatology
Incidence and Risk Factors Associated With Switching Between b/tsDMARD in PsA
MDedge Rheumatology
Risankizumab Safe for Long-Term Use in PsA
MDedge Rheumatology
DMARD-Naive and DMARD-Failure PsA Patients Show Similar Imaging Profile
MDedge Rheumatology
Bimekizumab Bests Risankizumab in PsA
MDedge Rheumatology
PsA Patients Initiating bDMARD Face High Risk for Interstitial Lung Disease
MDedge Rheumatology
Potential Predictive Biomarkers for Biologic Treatment Response in PsA
MDedge Rheumatology
Guselkumab Shows Early and Sustained Efficacy in PsA
MDedge Rheumatology
Bimekizumab Shows Long-Term Safety and Efficacy in Biologic-Naive and TNFi-IR PsA Patients
MDedge Rheumatology